Literature DB >> 15158096

DNA microarray screening of differential gene expression in bone marrow samples from AML, non-AML patients and AML cell lines.

Emma Louise Court1, M Ann Smith, Neil David Avent, John T Hancock, Lyn M Morgan, Atherton G Gray, J Graham Smith.   

Abstract

This study used cDNA microarray technology to compare gene expression profiles in acute myeloblastic leukaemia (AML) with cDNA dot-blot and real time PCR analysis of cDNA transcripts to confirm array data. Patient AML marrow samples and AML cell lines were compared with normal/non-AML samples. Screening revealed five particular genes to be significantly differentially expressed across the sample groups. The migration-inhibitory factor-related-proteins 8 and 14 (MRP-8 and MRP-14) genes, the products of which inhibit cell migration and differentiation were the most highly expressed in non-malignant cells. The high-mobility-group-protein gene (HMG-1) was up regulated in leukaemic samples and cell lines, which may be associated with aggressive disease. Also upregulated in malignant samples were genes encoding c-myc and glutathione-S-transferase pi (GSTP), the latter implicated in chemotherapy resistance. Faulty expression of such genes may contribute to the pathogenesis of AML and resistance to treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15158096     DOI: 10.1016/j.leukres.2003.11.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas.

Authors:  K Völp; M-L Brezniceanu; S Bösser; T Brabletz; T Kirchner; D Göttel; S Joos; M Zörnig
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

2.  The PKR-Like Endoplasmic Reticulum Kinase Promotes the Dissemination of Myc-Induced Leukemic Cells.

Authors:  Jun Gui; Kanstantsin V Katlinski; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Mol Cancer Res       Date:  2019-03-22       Impact factor: 5.852

3.  Myc roles in hematopoiesis and leukemia.

Authors:  M Dolores Delgado; Javier León
Journal:  Genes Cancer       Date:  2010-06

4.  Myeloid leukemia with transdifferentiation plasticity developing from T-cell progenitors.

Authors:  Pia Riemke; Melinda Czeh; Josephine Fischer; Carolin Walter; Saeed Ghani; Matthias Zepper; Konstantin Agelopoulos; Stephanie Lettermann; Marie L Gebhardt; Nancy Mah; Andre Weilemann; Michael Grau; Verena Gröning; Torsten Haferlach; Dido Lenze; Ruud Delwel; Marco Prinz; Miguel A Andrade-Navarro; Georg Lenz; Martin Dugas; Carsten Müller-Tidow; Frank Rosenbauer
Journal:  EMBO J       Date:  2016-08-29       Impact factor: 11.598

5.  Ribosomal protein S14 negatively regulates c-Myc activity.

Authors:  Xiang Zhou; Qian Hao; Jun-Ming Liao; Peng Liao; Hua Lu
Journal:  J Biol Chem       Date:  2013-06-17       Impact factor: 5.157

Review 6.  MYC oncogene in myeloid neoplasias.

Authors:  M Dolores Delgado; Marta Albajar; M Teresa Gomez-Casares; Ana Batlle; Javier León
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

7.  The role of high mobility group box 1 (HMGB1) in colorectal cancer.

Authors:  Dinç Süren; Mustafa Yıldırım; Özlem Demirpençe; Vildan Kaya; Arsenal Sezgin Alikanoğlu; Nurullah Bülbüller; Mustafa Yıldız; Cem Sezer
Journal:  Med Sci Monit       Date:  2014-03-31

8.  Inhibiting CCN1 blocks AML cell growth by disrupting the MEK/ERK pathway.

Authors:  Chang-Chun Niu; Chen Zhao; Zhong Yang; Xiao-Li Zhang; Jing Pan; Chen Zhao; Wei-Ke Si
Journal:  Cancer Cell Int       Date:  2014-08-16       Impact factor: 5.722

Review 9.  Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review.

Authors:  Austin H Nguyen; Sheila B Bhavsar; Erinn M Riley; Gabriel C Caponetti; Devendra K Agrawal
Journal:  Contemp Oncol (Pozn)       Date:  2017-01-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.